首页 > 市场调查报告书 > 製药

非专利药生技仿製药

市场调查报告书

商品编码

1471973

肿瘤生物相似药市场规模和预测、全球和地区份额、趋势和成长机会分析报告范围：按药物类别、癌症类型和配销通路

Oncology Biosimilars Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Class, Cancer Type, and Distribution Channel

出版日期: 2024年03月12日 | 出版商:

The Insight Partners | 英文 150 Pages | 商品交期: 1-5个工作天内

价格

简介目录

2023年肿瘤生物相似药市场价值为94.6亿美元，预计到2031年将达到247.1亿美元；预计 2023 年至 2031 年复合年增长率为 12.8%。

推动市场成长的关键因素是癌症发生率的激增，包括肺癌、大肠癌和乳癌；生物相似药的成本效益；肿瘤生物相似药的核准量增加。然而，生物相似药产品製造的高成本参与和复杂性阻碍了肿瘤生物相似药市场的成长

肿瘤生物相似药的市场趋势：

合资企业等合作模式可以帮助生物相似药製造商保持竞争力。透过与其他公司合作，他们可以快速有效地开发产品、获得资金并赢得临床医生和患者的信任。合作还可以提供对现有製造设施的访问，长期利益包括轻鬆访问未来的生产项目和早期市场渗透。以下是近期在肿瘤生物相似药市场上备受瞩目的合作的一些实例：

2023年7月，三星生物製品公司与辉瑞公司签署了策略合作伙伴协议，以实现辉瑞公司多产品组合的长期商业化生产。根据该协议，三星生物製品公司将为辉瑞提供额外的能力，用于大规模生产涵盖肿瘤学、发炎和免疫学的多产品生物相似药组合。

2022年3月，Cipla Medpro连同印度Cipla Limited的全资子公司与全球生物技术公司mAbxience签订合作协议，向南非提供肿瘤和呼吸系统相关生物相似药。该伙伴关係旨在确保该地区公正地获得负担得起的救生药物。

因此，生物相似药製造商之间的合作和临床试验预计将在未来几年带来新的肿瘤生物相似药市场趋势。

肿瘤生物相似药：细分市场概述

肿瘤生物相似药根据药物类别、癌症类型和配销通路进行细分。

依药物类别，市场分为单株抗体、粒细胞集落刺激因子和红血球生成刺激剂。 2023年，单株抗体细分市场占最大市场份额，预计2023年至2031年复合年增长率最高。。肺癌细分市场在 2023 年占据最大的肿瘤生物相似药市场份额，预计 2023 年至 2031 年复合年增长率最高。 2023 年，医院药局领域占据最大的市场份额，预计 2023 年至 2031 年复合年增长率最高。

全球肿瘤生物相似药报告的范围涵盖北美（美国、加拿大和墨西哥）、欧洲（德国、法国、义大利、英国、西班牙和欧洲其他地区）、亚太地区（中国、日本、印度、澳洲、韩国和亚太其他地区）、中东和非洲（南非、沙乌地阿拉伯、阿联酋以及中东和非洲其他地区）以及南美洲和中美洲（巴西、阿根廷和南美洲和中美洲其他地区）。 2023 年，北美占据了肿瘤生物相似药的主要份额，其次是欧洲；亚太地区的市场在预测期内以最高的复合年增长率成长。这归因于新兴市场医疗保健基础设施的发展、医疗保健支出的增加、利润丰厚的报销政策以及该地区越来越重视更好的患者治疗结果。

欧洲
- 德国
- 法国
- 义大利
- 西班牙
- 英国
- 欧洲其他地区
亚太
- 澳洲
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区
南美洲和中美洲
- 巴西
- 阿根廷
- 南美洲和中美洲其他地区

第 11 章：产业格局

併购
协议、合作、合资企业
新产品发布
扩张和其他策略发展

第 12 章：竞争格局

关键参与者的热图分析
公司定位与专注

第 13 章：肿瘤生物相似药市场 - 主要公司概况

Biocon
Celltrion Inc
Samsung Bioepis
Amgen Inc
Coherus BioSciences
Pfizer Inc
Sandoz International GmbH (A Novartis Division)
Teva Pharmaceutical Industries Ltd.
Lilly
BIOCAD

第 14 章：附录

简介目录

Product Code: TIPRE00002766

The oncology biosimilars market was valued at US$ 9.46 billion in 2023 and is anticipated to reach US$ 24.71 billion by 2031; it is projected to register a CAGR of 12.8% from 2023 to 2031.

Key factors driving the market growth are the surge in incidences of cancers, including lung cancer, colorectal cancer, and breast cancer; the cost-effectiveness of biosimilar drugs; and a rise in the approvals of oncology biosimilars. However, high-cost involvement and complexities in biosimilar product manufacturing hamper the oncology biosimilars market growth

Market Trends of the Oncology Biosimilars:

Collaboration models such as joint ventures can help biosimilar medicine manufacturers stay competitive. By collaborating with other companies, they can develop products quickly and effectively, access funding, and gain clinician and patient confidence. Collaboration can also provide access to established manufacturing facilities, and long-term benefits include easy access to future production projects and early market penetration. A few instances of recent, high-profile collaborations in the oncology biosimilars market are given below:

In July 2023, Samsung Biologics and Pfizer signed a strategic partnership agreement for the long-term commercial manufacturing of Pfizer's multi-product portfolio. Under this agreement, Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product biosimilar portfolio covering oncology, inflammation, and immunology.

In March 2022, Cipla Medpro, along with the wholly-owned subsidiary of Cipla Limited in India, entered into a partnership agreement with mAbxience, the global biotechnology company, to provide oncology and respiratory-related biosimilars to South Africa. The partnership is aimed to ensure unbiased access to affordable, life-saving medication in the region.

Therefore, the collaborations among manufacturers for biosimilars and clinical trials are expected to bring new oncology biosimilars market trends in the coming years.

Oncology Biosimilars: Segmental Overview

The oncology biosimilars is segmented on the basis of drug class, cancer type, and distribution channel.

The market, by drug class, is segmented into monoclonal antibodies, granulocyte colony-stimulating factor, and erythropoiesis-stimulating agents. In 2023, the monoclonal antibodies segment held the largest share of the market and is anticipated to register the highest CAGR from 2023 to 2031. The market, based on cancer type, is categorized into lung cancer, colorectal cancer, cervical cancer, breast cancer, stomach cancer, brain cancer, and others. The lung cancer segment held the largest oncology biosimilars market share in 2023 and is projected to register the highest CAGR from 2023 to 2031. The oncology biosimilars market is segmented based on distribution channels into hospital pharmacies, retail pharmacies, and online pharmacies. In 2023, the hospital pharmacy segment held the largest market share and is expected to register the highest CAGR from 2023 to 2031.Oncology biosimilars: Geographical Overview

The scope of the global oncology biosimilars report entails North America (the US, Canada, and Mexico), Europe (Germany, France, Italy, the UK, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). North America held a major oncology biosimilars share in 2023, followed by Europe; the market in Asia Pacific region is growing with the highest CAGR during the forecast period. This is attributed to developing healthcare infrastructure in emerging markets, rising healthcare expenditure, lucrative reimbursement policies, and increasing emphasis on better patient outcomes in the region.

1. Introduction

1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 Market Attractiveness Analysis

3. Research Methodology

4. Oncology Biosimilars Market Landscape

4.1 Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain

5. Oncology Biosimilars Market - Key Market Dynamics

5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints

6. Oncology Biosimilars Market - Global Market Analysis

6.1 Oncology Biosimilars - Global Market Overview
6.2 Oncology Biosimilars - Global Market and Forecast to 2031

7. Oncology Biosimilars Market - Revenue Analysis (USD Million) - By Drug Class, 2021-2031

7.1 Overview
7.2 Monoclonal Antibodies
7.3 Erythropoiesis-Stimulating Agents
7.4 Granulocyte Colony-Stimulating Factor (G-CSF)

8. Oncology Biosimilars Market - Revenue Analysis (USD Million) - By Cancer Type, 2021-2031

8.1 Overview
8.2 Colorectal Cancer
8.3 Cervical Cancer
8.4 Breast Cancer
8.5 Supportive Care
8.6 Lymphoma
8.7 Others

9. Oncology Biosimilars Market - Revenue Analysis (USD Million) - By Distribution Channel , 2021-2031

9.1 Overview
9.2 Hospital Pharmacy
9.3 Retail Pharmacy
9.4 Online Pharmacy

10. Oncology Biosimilars Market - Revenue Analysis (USD Million), 2021-2031 - Geographical Analysis

10.1 North America
- 10.1.1 North America Oncology Biosimilars Market Overview
- 10.1.2 North America Oncology Biosimilars Market Revenue and Forecasts to 2031
- 10.1.3 North America Oncology Biosimilars Market Revenue and Forecasts and Analysis - By Drug Class
- 10.1.4 North America Oncology Biosimilars Market Revenue and Forecasts and Analysis - By Cancer Type
- 10.1.5 North America Oncology Biosimilars Market Revenue and Forecasts and Analysis - By Distribution Channel
- 10.1.6 North America Oncology Biosimilars Market Revenue and Forecasts and Analysis - By Countries
  - 10.1.6.1 United States Oncology Biosimilars Market
    - 10.1.6.1.1 United States Oncology Biosimilars Market, by Drug Class
    - 10.1.6.1.2 United States Oncology Biosimilars Market, by Cancer Type
    - 10.1.6.1.3 United States Oncology Biosimilars Market, by Distribution Channel
  - 10.1.6.2 Canada Oncology Biosimilars Market
    - 10.1.6.2.1 Canada Oncology Biosimilars Market, by Drug Class
    - 10.1.6.2.2 Canada Oncology Biosimilars Market, by Cancer Type
    - 10.1.6.2.3 Canada Oncology Biosimilars Market, by Distribution Channel
  - 10.1.6.3 Mexico Oncology Biosimilars Market
    - 10.1.6.3.1 Mexico Oncology Biosimilars Market, by Drug Class
    - 10.1.6.3.2 Mexico Oncology Biosimilars Market, by Cancer Type
    - 10.1.6.3.3 Mexico Oncology Biosimilars Market, by Distribution Channel

Note - Similar analysis would be provided for below mentioned regions/countries

10.2 Europe
- 10.2.1 Germany
- 10.2.2 France
- 10.2.3 Italy
- 10.2.4 Spain
- 10.2.5 United Kingdom
- 10.2.6 Rest of Europe
10.3 Asia-Pacific
- 10.3.1 Australia
- 10.3.2 China
- 10.3.3 India
- 10.3.4 Japan
- 10.3.5 South Korea
- 10.3.6 Rest of Asia-Pacific
10.4 Middle East and Africa
- 10.4.1 South Africa
- 10.4.2 Saudi Arabia
- 10.4.3 U.A.E
- 10.4.4 Rest of Middle East and Africa
10.5 South and Central America
- 10.5.1 Brazil
- 10.5.2 Argentina
- 10.5.3 Rest of South and Central America

11. Industry Landscape

11.1 Mergers and Acquisitions
11.2 Agreements, Collaborations, Joint Ventures
11.3 New Product Launches
11.4 Expansions and Other Strategic Developments

12. Competitive Landscape

12.1 Heat Map Analysis by Key Players
12.2 Company Positioning and Concentration

13. Oncology Biosimilars Market - Key Company Profiles

13.1 Biocon
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments

Note - Similar information would be provided for below list of companies